ADVA
20.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has upgraded its complete portfolio of Oscilloquartz PTP grandmaster clocks, enabling power utilities to smoothly transition to packet network synchronization. The enhanced technology will empower electricity providers to evolve their infrastructure into smart grids based on Precision Time Protocol (PTP) power profiles, while at the same time supporting all legacy timing signals. Updates to ADVA’s Oscilloquartz pluggable solution, its compact small cell device, its mid-size PTP grandmasters and its fully redundant core timing technology ensure ultra-precise timing throughout the utility network. What’s more, the technology removes the risk of relying purely on satellite-based time sources through continuous monitoring, jamming and spoofing detection and AI-assisted analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005048/en/
“Our upgraded technology makes it simple to modernize utility infrastructure. Now, power network operators can achieve the accurate and stable synchronization needed to develop smart grid power networks built on packet-based solutions, while also maintaining legacy timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our technology provides a clear and cost-efficient path to robust and future-proof utility network synchronization. Its PTP timing delivery complements and replaces legacy protocols, enabling the accurate and resilient timing needed for emerging intelligent applications. Along with our multi-constellation GNSS receivers, PTP backup is also essential for protecting critical power networks. This ensures efficient operations and the best protection from malicious attacks.”
ADVA’s entire range of Oscilloquartz grandmaster clocks has been upgraded to meet the latest PTP profiles for time, frequency and phase synchronization in power utility networks. This includes the OSA 5401 small form-factor pluggable, the OSA 5405 for indoor and outdoor substation deployments, the OSA 5420 Series, and the highly scalable OSA 5430 and 5440 with 10Gbit/s interfaces and fully redundant hardware. The technologies enable an easy migration to an Ethernet-based timing network with support for PTP, Network Time Protocol (NTP) and SyncE, as well as IRIG-B, PPS and BITS legacy interfaces. PTP-based backup combined with multi-band GNSS receivers and advanced monitoring capabilities ensure that the upgraded solutions provide highly reliable delivery of precise timing information even during long GNSS outages. And, to create an ePRTC solution, ADVA’s Oscilloquartz cesium clocks can also be combined with the OSA 5420, 5430 or 5440. This delivers extended holdover of up to 70 nanoseconds for 14 days, even when GNSS signals are unavailable.
”By optimizing our synchronization technology, we’re enabling power utilities to achieve the stringent levels of precision necessary for synchronization from the substation to the core of the smart grid network. Our comprehensive portfolio empowers utilities to complement and then replace their legacy timing protocols with PTP. What’s more, our continually evolving software supports the broadest range of interfaces and profiles, ensuring a solution ready to grow with future needs,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. ”IRIG-B and NTP have served the utility industry well. But the future is all about PTP power profiles delivering new levels of precision and reliability to substations with or without GNSS. This upgrade ensures operators can rely on extremely accurate frequency, phase and time services without the threat of outages caused by jamming and spoofing.”
Watch this video for more information: https://youtu.be/iHA_TI32T6A .
Further details are also provided in these slides: https://adva.li/power-utilities-slides .
A supporting solution sheet is available here: https://adva.li/smart-grids-solution-sheet .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005048/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom